Vesalius Biocapital, a life sciences venture capital investor, has closed its fourth fund, Vesalius Biocapital IV, securing over €95 million of commitments. The company plans to invest in first and best-in-class European life science companies in drug development and digital health. The goal is to build a portfolio of 10-15 companies, providing capital and the […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!